Vivos Therapeutics, Inc.
VVOS
$2.57
$0.000.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 14.58M | 14.02M | 13.36M | 13.80M | 14.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.58M | 14.02M | 13.36M | 13.80M | 14.50M |
| Cost of Revenue | 5.57M | 5.60M | 5.49M | 5.53M | 5.94M |
| Gross Profit | 9.01M | 8.42M | 7.87M | 8.27M | 8.57M |
| SG&A Expenses | 20.82M | 21.23M | 23.25M | 24.84M | 26.95M |
| Depreciation & Amortization | 586.00K | 590.00K | 593.00K | 622.00K | 642.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.08M | 27.52M | 29.44M | 31.10M | 33.73M |
| Operating Income | -12.50M | -13.49M | -16.08M | -17.30M | -19.23M |
| Income Before Tax | -12.57M | -12.05M | -15.64M | -13.58M | -15.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.57 | -12.05 | -15.64 | -13.58 | -15.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.57M | -12.05M | -15.64M | -13.58M | -15.41M |
| EBIT | -12.50M | -13.49M | -16.08M | -17.30M | -19.23M |
| EBITDA | -11.91M | -12.91M | -15.48M | -16.67M | -18.58M |
| EPS Basic | -5.62 | -6.98 | -11.00 | -11.08 | -13.45 |
| Normalized Basic EPS | -3.51 | -4.36 | -6.87 | -6.93 | -8.42 |
| EPS Diluted | -5.62 | -6.98 | -11.00 | -11.08 | -13.45 |
| Normalized Diluted EPS | -3.51 | -4.36 | -6.87 | -6.93 | -8.42 |
| Average Basic Shares Outstanding | 13.57M | 8.15M | 6.12M | 4.81M | 4.52M |
| Average Diluted Shares Outstanding | 13.57M | 8.15M | 6.12M | 4.81M | 4.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
